Prana completes recruitment in IMAGINE trial Prana Biotechnology announced that it has completed recruitment in the IMAGINE trial, a 12 month Phase II trial testing PBT2, the Company's drug in development for Alzheimer's Disease. The double-blind placebo controlled trial has enrolled 41 patients with prodromal or mild Alzheimer's Disease in Melbourne, Australia. One additional patient may be included in the trial, subject to final screening procedures this week. All trial participants are undergoing brain scans to measure PBT2's effect on amyloid deposits in the brain and effects on increasing brain activity.
News For PRAN From The Last 14 Days
Check below for free stories on PRAN the last two weeks.
Prana granted orphan status for treatment of Huntington disease The FDA posted on its website that Prana Biotechnology has been granted orphan status for its treatment of Huntington's disease. Reference Link